Stanley K. Liu, Ph.D.
Affiliations: | 2000 | University of Toronto, Toronto, ON, Canada |
Area:
Molecular BiologyGoogle:
"Stanley Liu"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Jane McGlade | grad student | 2000 | University of Toronto | |
| (Identification and characterization of Gads - a novel hematopoietic-specific adaptor protein - in T cell receptor signaling.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Glicksman RM, Loblaw A, Morton G, et al. (2023) Randomized trial of concomitant hypofractionated IMRT boost versus conventional fractionated IMRT boost for localized high-risk prostate cancer (pHART2-RCT). International Journal of Radiation Oncology, Biology, Physics |
| Ong WL, Cheung P, Chung H, et al. (2023) To boost or not to boost - pooled analyses from two-fraction stereotactic ablative radiotherapy (SABR) trials for localised prostate cancer. International Journal of Radiation Oncology, Biology, Physics |
| Mesci A, Ahmadi E, Ali A, et al. (2023) F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer. Clinical and Translational Radiation Oncology. 39: 100583 |
| Correa RJM, Morton G, Chung HT, et al. (2022) Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter? Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 169: 51-56 |
| Musunuru HB, Cheung P, Vesprini D, et al. (2021) Gantry-based 5-fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes from 2 Prospective Studies comparing SABR Boost with MR Dose Painted HDR Brachytherapy Boost. International Journal of Radiation Oncology, Biology, Physics |
| Glicksman RM, Liu SK, Cheung P, et al. (2021) Elective nodal ultra hypofractionated radiation for prostate cancer: safety and efficacy from four prospective clinical trials. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |
| Khoo A, Liu LY, Nyalwidhe JO, et al. (2021) Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. Nature Reviews. Urology |
| Glicksman RM, Loblaw A, Morton G, et al. (2021) Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |
| Musunuru HB, Cheung P, Vesprini D, et al. (2021) Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): efficacy, toxicity and quality of life. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |
| Corkum M, Loblaw A, Hasan Y, et al. (2020) Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |